jeudi 21 mars 2019

Onco Actu du 21 mars 2019


1. BIOLOGIE



TRACERx Study Characterizes Immune Relationship to Lung Tumor Evolution [Genome Web]











Protein BRCA1 as a Stress Coach [Universität Würzburg]











The immune system preys on growing lung cancers, forcing them to evolve to survive [Cancer Research UK]










2.11 ETIOLOGIE - ALIMENTATION



Hot tea linked to increased risk of esophageal cancer [UPI]











Headlines saying ‘hot tea causes oesophageal cancer’ miss crucial details [Cancer Research UK]










2.6 ETIOLOGIE - ENVIRONNEMENT



Jury finding upends Bayer's Roundup defense strategy: experts [Reuters]











3.1.1 PRÉVENTION - TABAC - E-CIGS



San Francisco officials propose ban on sale of e-cigarettes [The Guardian]











3.3 PRÉVENTION - VACCINS



Merck's refreshed HPV vaccine push puts Mom in the spotlight [Fierce Pharma]











4.12 BIOPSIES LIQUIDES



A liquid biopsy that combines Illumina’s ‘ultradeep’ sequencing with Grail’s machine learning [Fierce Biotech]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



Taking the Uncertainty Out of Interpreting BRCA Variants [JAMA]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



NHS removes cervical screening contract from Capita [The Guardian]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



New class of drugs could treat ovarian cancer [University of Manchester]











Pushing Myc inhibition closer to the clinic [VHIO]











Protein-slaying drugs could be the next blockbuster therapies [Nature]










Researchers identify potential new combination treatment for pancreatic cancer [UCLA]











5.10 TRAITEMENTS - ESSAIS



Ground Breaking Pancreatic Cancer Trial Reaches Patient Milestone [University of Glasgow]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Pfizer, Merck KGaA scrap yet another Bavencio ovarian cancer trial [Fierce Pharma]











Pfizer, Merck KGaA miss again in ovarian cancer [Biopharma Dive]











GlaxoSmithKline sets its sights on a quick leap into the big PD-1/L1 game — will anyone notice? [EndPoints]











5.2 PHARMA



FDA issues partial hold on studies of AbbVie, Roche drug in multiple myeloma [Biopharma Dive]











An Unexpected Halt in Multiple Myeloma for Venetoclax [In The Pipeline]











5.2.3 PHARMA - ÉCONOMIE



Biosimilar Groups Offer Proposals to Help US Better Mirror EU Successes [RAPS]











5.9 AACR



Parker Institute to Share Pancreatic Cancer Trial Results, Microbiome and Immunotherapy Research, and New CAR-T Approaches at AACR 2019 [Parker Institute]











6. LUTTE CONTRE LES CANCERS



Cancer doctor shortage ‘will impact patients’, says Royal College [Cancer Research UK]











6.8 COMMUNICATION



Hancock accused of 'astonishing ignorance' after he speaks about his prostate cancer risk [The Telegraph]











6.9 CONTROVERSES



Statisticians' Call To Arms: Reject Significance And Embrace Uncertainty! [NPR]











Scientists rise up against statistical significance [Nature]